Dr. Shelley Chu joined Frazier Healthcare in 2005 as a Vice President and became a Principal in 2007.  Dr. Chu is a member of Frazier Healthcare’s biopharma investment team and has played significant roles in the firm’s investments in Intradigm Corporation, Cadence Pharmaceuticals, Cerexa, and Arete Therapeutics among others.  (more…)

W. Scott Harkonen, M.D., is President and Chief Executive Officer of CoMentis, a pharmaceutical company engaged in the discovery and development of small-molecule drugs to treat Alzheimer’s disease, age-related macular degeneration (AMD) and cognitive disorders.

(more…)

Dr. Steven Targum serves as Chief Medical Officer at BrainCells, Inc. (BCI), a biopharmaceutical company focused on the development of breakthrough small molecule therapeutics for diseases of the central nervous system (CNS).  (more…)

Martin Tolar, M.D., Ph.D., is Chief Scientific Officer at CoMentis, a pharmaceutical company engaged in the discovery and development of small-molecule drugs to treat Alzheimer’s disease, age-related macular degeneration (AMD) and cognitive disorders. (more…)

Dr. Yamada joined Frazier Healthcare Ventures in 2006 as a Senior Advisor to the biopharma team. (more…)

Henry Hsu, M.D., Chief Medical Officer, CoMentis, a pharmaceutical company engaged in the discovery and development of small-molecule drugs to treat Alzheimer’s disease, age-related macular degeneration (AMD) and cognitive disorders. (more…)

August M. Watanabe, MD, joined Frazier Healthcare Ventures in 2005 as Senior Advisor to the Biopharma team.   (more…)

MedImmune Ventures, Inc. is a wholly owned venture capital subsidiary of MedImmune, Inc. It was created in 2002 to leverage the company’s expertise in discovering, developing and commercializing biotechnology products, as well as its financial resources, to transform new ideas in biotechnology into successful products and companies. (more…)

Joe Amprey is a member of the Metastatix Board of Directors and is also a Principal at MedImmune Ventures. (more…)

Drew Senyei, MD, is a managing director at Enterprise Partners  where he leads the life science practice. Drew focuses on investments in pharmaceuticals, biopharmaceuticals, diagnostics, medical devices and consumer healthcare. (more…)